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Abstract
The question of whether influenza is transmitted to a significant degree by aerosols remains 
controversial, in part, because little is known about the quantity and size of potentially infectious 
airborne particles produced by people with influenza. In this study, the size and amount of aerosol 
particles produced by nine subjects during coughing were measured while they had influenza and 
after they had recovered, using a laser aerosol particle spectrometer with a size range of 0.35 to 10 
μm. Individuals with influenza produce a significantly greater volume of aerosol when ill 
compared with afterward (p = 0.0143). When the patients had influenza, their average cough 
aerosol volume was 38.3 picoliters (pL) of particles per cough (SD 43.7); after patients recovered, 
the average volume was 26.4 pL per cough (SD 45.6). The number of particles produced per 
cough was also higher when subjects had influenza (average 75,400 particles/cough, SD 97,300) 
compared with afterward (average 52,200, SD 98,600), although the difference did not reach 
statistical significance (p = 0.1042). The average number of particles expelled per cough varied 
widely from patient to patient, ranging from 900 to 302,200 particles/cough while subjects had 
influenza and 1100 to 308,600 particles/cough after recovery. When the subjects had influenza, an 
average of 63% of each subject's cough aerosol particle volume in the detection range was in the 
respirable size fraction (SD 22%), indicating that these particles could reach the alveolar region of 
the lungs if inhaled by another person. This enhancement in aerosol generation during illness may 
play an important role in influenza transmission and suggests that a better understanding of this 
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phenomenon is needed to predict the production and dissemination of influenza-laden aerosols by 
people infected with this virus.
Keywords
airborne particles; airborne transmission; disease transmission; human; respiratory infections
Introduction
Influenza is a highly contagious respiratory disease that is of great concern to the public 
health community because of the annual burden from the illness and the possibility of a 
severe pandemic with high rates of morbidity and mortality. Influenza is thought to be 
spread by direct person-to-person transfer of infectious secretions, by indirect transfer of 
secretions via fomites, by large ballistic spray droplets that are produced during coughing or 
sneezing and splash onto mucous membranes, and by the inhalation and deposition of 
airborne virus-laden particles.(1) However, the relative importance of these routes of 
transmission is unclear and appears to depend on multiple factors, including temperature and 
humidity, the virus concentration in respiratory secretions, the distance from the source to 
the recipient, and the genotype of the virus.(2,3)
The possibility of airborne transmission in particular is hotly debated, with some studies 
suggesting that this pathway plays a critical role in the spread of influenza(1,4) while others 
concluding that it does not.(5) This controversy had a direct impact on public health policy 
during the 2009 novel H1N1 influenza pandemic; some health care institutes such as the 
U.S. Institute of Medicine recommended that health care workers in close contact with 
influenza patients wear respirators to prevent possible airborne transmission,(6) while other 
organizations such as the World Health Organization did not.(7)
Disagreement over the potential for the airborne transmission of influenza occurs in part 
because the quantity and size of potentially infectious aerosols produced by people with 
influenza have not been well characterized. Several studies have examined aerosol particle 
generation by people during coughing, speaking, sneezing, and breathing (reviewed by 
Gralton(8) and Nicas(9)). Most of these studies used healthy subjects, but a few have looked 
at aerosol production by individuals with respiratory viral infections, including 
influenza(10–12) and rhinovirus.(10,13) All of these studies have consistently found a 
tremendous variation in the numbers of aerosol particles expelled by individuals. Edwards et 
al.(14) tested 11 healthy subjects and reported that the concentration of particles in their 
exhaled breath varied from 1 particle/liter to over 10,000 particles/liter. Fabian et al.(11) 
tested 10 patients with influenza and found that the concentration of particles exhaled by 
these subjects ranged from 67 to 8500 particles/liter of air; similar results were later reported 
for patients with rhinovirus infections.(13) Almstrand et al.(15) also found that the exhaled 
particle concentrations varied considerably from subject to subject and with the depth of 
breathing, but that the exhaled concentrations for each subject were fairly consistent during 
repeated testing for each respiratory maneuver studied.
Lindsley et al. Page 2













Although these papers and others have added considerably to the body of knowledge about 
respiratory aerosol production, one important question that remains unanswered is how 
respiratory infections affect aerosol particle production by patients. Because respiratory 
infections generally increase airway mucus production, it is typically assumed that aerosol 
production also increases, but the actual amount of any change is unknown, and it is also 
unclear whether the particle size or distribution of the aerosol is shifted. The studies cited 
above that looked at particle production in individuals with respiratory infections also 
included healthy individuals in some cases, but because of the large interpersonal variability 
in aerosol production, it is impossible to know if any differences observed are due to illness 
or other factors.
This study measured aerosol particle production during coughing by patients while they had 
an active influenza infection, and then measured cough aerosol production by these same 
patients after they had recovered. By performing the first direct comparison of respiratory 
aerosol production during and after illness, these results show more clearly how influenza 
affects aerosol generation. A better understanding of the effects of influenza on aerosol 
production will help with efforts to study the potential for the airborne transmission of this 
illness and to devise interventions to reduce its spread.
Methods
Equipment
The cough particle measurement system used in these experiments included a HEPA-filtered 
enclosure (Model 100-Plus; Envirco Corporation, Sanford, N.C.), an ultrasonic spirometer 
(EasyOne; ndd Medical Technologies, Andover, Mass.), and a 20-L stainless steel box that 
served as a collection chamber for the cough aerosols (Figure 1). The cough aerosol 
collection chamber was fitted with an inlet port for the spirometer and two outlets. A Wide-
Range Particle Spectrometer (WPS) (Model M1000XP; MSP Corporation, Shoreview, 
Minn.) was connected to the chamber to analyze the cough aerosols. The WPS includes a 
laser particle spectrometer (LPS) to measure larger aerosol particles and a differential 
mobility analyzer-condensation particle counter (DMA-CPC) to measure smaller particles. 
According to the manufacturer, the LPS detection range is 0 to 500,000 particles/liter, while 
the DMA-CPC detection range is 20,000 to 1010 particles/liter. Most of the cough particle 
concentrations were below the detection limit of the DMA-CPC, and thus, only the LPS data 
are reported here. A 32-L/min air pump (Model 1532; Gast Manufacturing, Benton Harbor, 
Mich.) was also connected to the chamber to remove particles from it between tests.
Test Procedure
All procedures involving human subjects were reviewed and approved by the National 
Institute for Occupational Safety and Health (NIOSH) and West Virginia University (WVU) 
Institutional Review Boards. Written informed consent was obtained from all study 
participants.
During February and March 2009, patients presenting to WELLWVU Student Health with 
influenza-like symptoms were recruited. To be included in the study, subjects were required 
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to be male or non-pregnant female, age 18 to 35, lifetime non-smoker, have influenza-like 
symptoms including fever for 3 days or less, in otherwise good health, and must not have 
been vaccinated against influenza within the last 6 months. Subjects were asked a few 
questions about their general health, including current respiratory symptoms or illnesses. 
Their oral temperature was taken and two nasal swabs were collected, with the first one used 
for a standard clinical rapid influenza test (QuickVue Influenza test, Quidel Corp., San 
Diego, Calif.). If the rapid test was negative, the second swab was sent to a contract 
laboratory for analysis by polymerase chain reaction (PCR). The study technician then gave 
the participant specific instructions for the cough procedure.
For each test, the participant was seated directly in front of the HEPA-filtered air cabinet 
and asked to breathe normally for 5 min to remove background aerosols from their 
respiratory tract. During this time, the air pump was used to remove background aerosols 
from the collection chamber. After 5 min the air pump was turned off, and the subject was 
asked to exhale completely, inhale as much as possible, seal their lips around the spirometer 
mouthpiece, and cough. The subjects were asked to cough forcefully using as much of the 
air in their lungs as possible and to remove their lips from the mouthpiece at the end of the 
cough. After coughing, the subject resumed breathing HEPA-filtered air while the aerosol 
was collected and analyzed for 5 min. After analysis, the chamber was evacuated for 2 min 
using the air pump, and the subject was asked to repeat the cough procedure two more times 
for a total of three coughs. After each participant was finished, the spirometer mouthpiece 
was changed, and the HEPA cabinet and equipment were cleaned with disinfectant.
After completing the initial cough procedure, participants were scheduled for a return visit 
approximately 2 weeks later. On the return visit, the participants were asked if they had any 
influenza-like symptoms. If the person was no longer exhibiting symptoms, they were again 
asked to perform three coughs using the same procedure as above.
Calculations
The LPS provided aerosol particle counts in 24 size bins with optical diameters from 0.35 to 
10 μm (Figure 2). Particle size and count data were collected continuously during each trial. 
The data were adjusted for the fraction of the sample flow stream that was counted by the 
LPS (0.7), the sample count time vs. the time for the total measurement cycle (30 vs. 51 
sec), and the fraction of the air in the collection chamber that was sampled (5 of 20 L) to get 
the total number of aerosol particles and calculate the average number of particles/ cough. 
Because the data distributions are somewhat skewed, the average and the median of each 
data set are reported, along with the standard deviation, the geometric mean, and the 
geometric standard deviation (GSD). For the particle size distribution parameter calculations 
(count median diameter, volume median diameter, and GSD), the particle counts for each 
size bin were summed for all three coughs, and the parameters were calculated based on the 
summed counts. For each subject, the average results from all three coughs while ill were 
compared with the average results from all three coughs after recovery using a paired two-
tailed t-test. Results were considered significant if p ≤ 0.05.
The total volume of the aerosol particles in each size bin was estimated by assuming that the 
particles were spherical and that the physical diameter was approximately equal to the 
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optical diameter. The volume of each aerosol particle was then computed, and the number of 
particles in each size bin was multiplied by the volume of each particle to get the total 
aerosol particle volume for each size bin.
The ACGIH® defines respirable aerosol particles as those particles small enough to reach 
the alveolar region of the lungs. The aerodynamic cutoff diameter for respirable particles is 
4 μm.(16) To estimate the fraction of the cough aerosol that was in the respirable size range, 
the particles were assumed to have a density of 1.704 g/cm3 based on the calculation by 
Nicas et al.(9) The particle optical diameters were thus multiplied by √1.704 to get the 
aerodynamic diameter.(17) The aerosol particle volume in each size bin was then multiplied 
by the corresponding respirable fraction for that aerodynamic diameter as calculated using 
the ACGIH's formula.(16)
Results
Twenty-three subjects were recruited for this study. Of these, nine subjects (six male, three 
female, ages 18 to 22) were confirmed to have influenza on their first visit and returned for a 
second test session after their symptoms had resolved (average time from first visit to 
second 13.8 days, SD 1.3). A typical plot of the number of aerosol particles detected per 
cough in each size bin is shown in Figure 2. The number of particles expelled per cough 
while the subjects had influenza varied considerably, with an average of 75,400 particles/
cough, a median of 46,400, and a standard deviation (SD) of 97,300 (Figure 3, Table I). 
After the patients had recovered, their average and median particles per cough were lower 
(average 52,200; median 8300; SD 98,600), although the difference did not reach statistical 
significance (p = 0.1042).
The volume of the aerosol particles (that is, the total physical volume of the particles 
themselves, not the air volume of the coughs) also varied from patient to patient. When the 
patients had influenza, their average aerosol volume was 38.3 pL/cough; after patients 
recovered, the average volume was 26.4 pL/cough. In this case, the difference in aerosol 
volume during sickness and after recovery was statistically significant (p = 0.0143). The 
volume of aerosol particles per liter of air coughed changed in a similar manner; the average 
cough aerosol volume per liter of air was 14.9 pL/l when ill and 8.5 pL/l after recovery 
(Figure 4), and this difference was also significant (p = 0.0215).
The air volume of each cough did not change significantly during and after illness (p = 
0.7201); the average cough air volume was 2.48 L when the subjects had influenza (SD 
1.09) and 2.33 L after recovery (SD 1.00). The peak airflow during coughing increased 
somewhat after recovery; the peak flow was 5.33 L/second with influenza (SD 1.36) and 
5.86 L/sec after recovery (SD 1.51). However, the difference did not reach statistical 
significance (p = 0.1018).
The count median diameter (CMD) of the cough aerosol particles was fairly similar for all 
subjects and did not vary significantly during and after illness (p = 0.9340). When the 
subjects had influenza, the CMDs of all the cough aerosols were between 0.57 and 0.71 μm 
(average 0.63 μm, SD 0.05), and the geometric standard deviations (GSD) were between 
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1.54 and 1.83. After the subjects had recovered, the cough aerosol CMDs ranged from 0.57 
to 0.89 μm (average 0.63 μm, SD 0.100), and the GSDs were between 1.53 and 2.28. Similar 
results were seen for the volume median diameters (VMD); the average cough aerosol VMD 
while ill was 2.44 μm (SD 1.17) and was 2.24 μm (SD 1.50) after recovery. The GSDs 
ranged from 1.66 to 2.31 while ill and 1.54 to 2.21 after recovery. The difference in VMD 
while ill and after recovery also was not statistically significant (p = 0.7780).
The ambient temperature during testing was 21° (SD 1) and the relative humidity was 28% 
(SD 8%). The experimental data for all subjects are presented as an online supplement.
Discussion
The ability of influenza to spread by airborne transmission is a critical issue for those in the 
public health community who must plan for a possible pandemic. However, many questions 
remain about the production of potentially infectious aerosols by people with influenza. Our 
study shows that people produce aerosols with a greater volume of particles when they are 
sick with influenza compared with after they have recovered. Our results also show that the 
increase in particle volume occurs across a broad range of particle sizes, and that the overall 
CMD and VMD of the cough particle size distribution do not change significantly after 
recovery from the illness.
The number of cough aerosol particles expelled by subjects in our study varied greatly from 
patient to patient. The number of particles generated ranged from a low of 400 particles/
cough to a high of 516,800 particles/cough while subjects had an influenza infection, and 
300 to 362,700 particles/cough after recovery. These results are consistent with those 
reported by others; virtually all studies of human aerosol particle generation that have 
compared subjects have found tremendous person-to-person variation.(8–13) This 
phenomenon may lead to a “superspreader” effect; that is, if some people produce much 
greater quantities of infectious aerosols, they may be much more likely to spread influenza 
to others.(9,18)
The cough aerosol particle volume also varied greatly from patient to patient; the average 
aerosol volumes ranged from 2.4 to 144 pL/cough when ill and 0.5 to 145 pL/cough after 
recovery. Interestingly, the ratio of cough aerosol volume when sick to the volume after 
recovery was more consistent; this ratio was always between 0.99 and 5.23 and had an 
average of 2.77 (SD 1.55). Thus, even though the absolute volume of aerosol coughed out 
by the patients varied greatly, the change in cough aerosol volume due to influenza for a 
given patient was more predictable. This was also true for the aerosol volume per liter of 
cough; in this case, the ratio ranged from 1.08 to 6.95, with an average of 2.79 (SD 1.87).
The respirable fraction of influenza-laden aerosols is of particular concern because these 
particles are capable of reaching the alveolar region of the lung during inhalation; human 
challenge studies have suggested that the infectious dose required for influenza to develop is 
considerably lower for particles depositing deeply into the lungs compared with particles 
depositing in the nasal region.(19) For our subjects, an average of 63% of the cough aerosol 
particle volume that was detected was in the respirable particle fraction while the subject 
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had influenza (SD 22%). Cough aerosols have a much broader size range(8,9) than was 
covered by our instrument (0.35 to 10 μm), and thus our data do not mean that 63% of the 
entire cough aerosol was in the respirable fraction.
However, our results do show that a substantial volume of cough aerosol particles are 
produced that are in the respirable fraction, and thus potentially capable of reaching the 
alveolar region of the lungs. It is also interesting to compare this result with other reports of 
the sizes of influenza-laden airborne particles; a study of cough aerosols collected from 
influenza patients found that 65% of the influenza virus RNA was contained in particles in 
the respirable size fraction,(12) and two previous studies of airborne particles in a hospital 
emergency department(20) and an urgent care clinic(21) found that 53% and 42% of the 
influenza virus RNA was in particles in the respirable size fraction. Taken together, these 
studies all suggest that a substantial portion of the airborne particles containing influenza 
that are expelled by patients are in the respirable size range and support the hypothesis that 
influenza could in fact be transmitted by the airborne route.
The total volume of the expelled particles recorded during our experiments was considerably 
lower than the amounts that have been reported by other researchers.(22–24) The primary 
reason for this is likely because these authors included much larger particles in their 
measurements (up to 2 mm for one study).(23) Since a 2-mm particle has a volume that is 
109 greater than a 2-μm particle, a small number of large particles can have a tremendous 
impact on the measurement of the total volume expelled. These larger drops fall very 
quickly (in fact, they were usually collected onto nearby settling plates during the 
experiments), while smaller droplets are capable of remaining airborne for an extended 
period. Thus, these results also illustrate the critical role of particle size in airborne disease 
transmission. At close range, larger drops can be important because of their greater volume 
and subsequent pathogen content, but as one moves farther away from an infected person, 
smaller particles may gradually become more important because they are able to stay 
airborne longer, reach more people, and are more easily inhaled.
Finally, some of the limitations of our study must be noted. The participants were young, 
ambulatory, otherwise healthy adults, and thus their results may not be representative of a 
broader and more diverse population. The number of subjects was small, which may be 
important given the large person-to-person variation seen in aerosol production. Our 
subjects were all symptomatic at the time of initial testing, but they were likely at different 
stages of their illness and some were more ill than others; both of these factors may 
influence aerosol production. Aerosol particles toward the upper limit of the WPS (10 μm) 
were more likely than small ones to deposit by impaction or settling before detection and 
thus may have been in our cough aerosol measurement system. Finally, it is not known how 
much influenza virus was contained in the airborne particles, how the influenza virus 
content varies with particle size, or how the amount of virus in each particle changes over 
the course of the illness.
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People with influenza release potentially infectious aerosol particles when they cough, 
sneeze, speak, and breathe. However, many questions remain about the likelihood of the 
transmission of influenza from person to person by the airborne route. Our study shows for 
the first time that individuals with influenza cough out a greater volume of aerosol particles 
than they do when they are healthy. Further, many of these particles are in the respirable size 
fraction and thus can be easily inhaled and drawn down into the deepest parts of the lungs 
where they may be more likely to cause an infection. This enhancement in aerosol 
generation may play an important role in influenza transmission and suggests that a better 
understanding of this phenomenon is needed to predict the production and dissemination of 
influenza-laden aerosols by people infected with this virus.
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Cough aerosol particle measurement system.
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Number of particles per cough for different particle sizes for Subject 8. The number of 
particles detected per cough is shown while the subject had influenza and after recovery. 
Particle sizes are optical diameters. Each bar shows the average of three coughs. Error bars 
show the standard deviation.
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Number of particles per cough during influenza and after recovery. For each subject, the 
total number of aerosol particles per cough from 0.35 to 10 μm in optical diameter is shown 
while they had influenza and after they had recovered. Each bar shows the average of three 
coughs. Error bars show the standard deviation.
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Volume of aerosol particles per liter of air coughed during influenza and after recovery. 
Total volume of aerosol particles expelled in picoliters per liter of air coughed (pL/l) is 
shown for each subject with influenza and after they had recovered. Each bar shows the 
average of three coughs. Error bars show the standard deviation.
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